• EyePoint Pharmaceuticals, Inc. (NasdaqGM:EYPT) was recently added to multiple Russell growth indices, including the Russell 3000 Growth, 2000 Growth, 2500 Growth, Microcap Growth, Small Cap Comp Growth, and 3000E Growth benchmarks.
• This broad inclusion across Russell growth benchmarks can increase EyePoint’s visibility with institutional investors and index-tracking funds, potentially deepening liquidity and reshaping how the company is viewed within small- and mid-cap growth portfolios.
• We’ll now examine how EyePoint’s broad Russell growth index inclusion may influence its existing wet-AMD focused investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

EyePoint Investment Narrative Recap

To own EyePoint, you need to believe DURAVYU can move from late‑stage trials to approval and commercialization before cash pressures and competition bite. The broad Russell growth index additions may support trading liquidity and visibility, but they do not change the core near term catalyst of Phase 3 DURAVYU data or the key risk of ongoing heavy losses with minimal current revenue.

The most relevant recent development alongside the index news is the May 2026 update that the DSMC’s third review of the LUGANO and LUCIA Phase 3 wet AMD trials recommended they continue without changes, with favorable interim safety in more than 190 patients. That progress keeps the DURAVYU timeline intact, which is central to how investors might interpret any liquidity or perception benefits from the new Russell index inclusions.

Yet the real concern investors should be aware of is how limited cash runway interacts with...

EyePoint's narrative projects $360.0 million revenue and $70.7 million earnings by 2029.

Uncover how EyePoint's forecasts yield a $37.00 fair value, a 162% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$250.8 million by 2028, yet Russell index inclusion may test whether such rapid growth and heavy R&D spending can coexist sustainably.

Explore 3 other fair value estimates on EyePoint - why the stock might be worth just $37.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.